Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD)
by Doug Wharley · The Cerbat GemBeOne Medicines (NASDAQ:ONC – Get Free Report) and Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Risk and Volatility
BeOne Medicines has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.
Valuation and Earnings
This table compares BeOne Medicines and Relmada Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeOne Medicines | $3.81 billion | 10.16 | -$644.79 million | $0.51 | 640.55 |
| Relmada Therapeutics | N/A | N/A | -$79.98 million | ($1.80) | -2.27 |
Relmada Therapeutics has lower revenue, but higher earnings than BeOne Medicines. Relmada Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by insiders. Comparatively, 20.7% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings for BeOne Medicines and Relmada Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 1 | 1 | 12 | 0 | 2.79 |
| Relmada Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
BeOne Medicines presently has a consensus price target of $365.79, indicating a potential upside of 11.97%. Relmada Therapeutics has a consensus price target of $10.00, indicating a potential upside of 144.80%. Given Relmada Therapeutics’ higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than BeOne Medicines.
Profitability
This table compares BeOne Medicines and Relmada Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 1.38% | 5.52% | 3.17% |
| Relmada Therapeutics | N/A | -269.49% | -205.22% |
Summary
BeOne Medicines beats Relmada Therapeutics on 9 of the 13 factors compared between the two stocks.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
About Relmada Therapeutics
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.